227 related articles for article (PubMed ID: 19758641)
1. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
Shuch B; Said J; La Rochelle JC; Zhou Y; Li G; Klatte T; Kabbinaavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Nov; 182(5):2164-71. PubMed ID: 19758641
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.
Silagy AW; Flynn J; Mano R; Blum KA; Marcon J; DiNatale RG; Sanchez A; Carlo MI; Motzer RJ; Coleman JA; Russo P; Ostrovnaya I; Chen YB; Hakimi AA
Urol Oncol; 2019 Nov; 37(11):811.e9-811.e16. PubMed ID: 31521530
[TBL] [Abstract][Full Text] [Related]
5. Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities.
Deuker M; Stolzenbach F; Rosiello G; Palumbo C; Martin T; Tian Z; Chun FK; Saad F; Shariat SF; Kapoor A; Karakiewicz PI
J Urol; 2020 Oct; 204(4):671-676. PubMed ID: 32250728
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
7. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
Shuch B; Bratslavsky G; Shih J; Vourganti S; Finley D; Castor B; Treat E; Linehan WM; Pantuck AJ; Said JW; Belldegrun AS
BJU Int; 2012 Jun; 109(11):1600-6. PubMed ID: 22221668
[TBL] [Abstract][Full Text] [Related]
8. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?
O'Malley RL; Brewer KA; Hayn MH; Kim HL; Underwood W; Pili R; Schwaab T
Urology; 2011 Sep; 78(3):595-600. PubMed ID: 21777963
[TBL] [Abstract][Full Text] [Related]
10. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
Adashek JJ; Zhang Y; Skelton WP; Bilotta A; Chahoud J; Zemp L; Li J; Dhillon J; Manley B; Spiess PE
Front Oncol; 2020; 10():627025. PubMed ID: 33643921
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy for pT3b-T4 M1 renal cell carcinoma in 39 patients: single center analysis.
Takagi T; Kondo T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Int J Urol; 2012 Sep; 19(9):875-9. PubMed ID: 22568824
[TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
Cheville JC; Lohse CM; Zincke H; Weaver AL; Leibovich BC; Frank I; Blute ML
Am J Surg Pathol; 2004 Apr; 28(4):435-41. PubMed ID: 15087662
[TBL] [Abstract][Full Text] [Related]
14. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
15. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience.
Silagy AW; Mano R; Blum KA; DiNatale RG; Marcon J; Tickoo SK; Reznik E; Coleman JA; Russo P; Hakimi AA
Urology; 2020 Feb; 136():169-175. PubMed ID: 31726184
[TBL] [Abstract][Full Text] [Related]
16. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
[TBL] [Abstract][Full Text] [Related]
19. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
20. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
